Document Detail

Zoledronic acid in genitourinary cancer.
MedLine Citation:
PMID:  23615978     Owner:  NLM     Status:  Publisher    
Bone metastases are a common complication of advanced prostate cancer and while they are less common in non-prostate genitourinary (GU) malignances, they have been reported in up to 35 % of patients with advanced renal cell carcinoma and bladder cancer. Furthermore, they may occur in more than two-thirds of those patients with bladder cancer who develop distant metastases. In the absence of bone-targeted therapies, approximately 50 % of all patients with metastatic bone disease from GU cancers experience at least one skeletal-related event within their lifetime. Zoledronic acid is a bisphosphonate that has been shown to delay or prevent the development of skeletal complications in patients with bone metastases and reduce bone pain in these patients. Furthermore, zoledronic acid has also demonstrated the ability to prevent osteopenia, which may occur with the prolonged use of some pharmacological interventions in patients with cancer.
M A Climent; U Anido; M J Méndez-Vidal; J Puente
Related Documents :
24250198 - Cabazitaxel: a novel taxane for metastatic castration-resistant prostate cancer-current...
23444208 - Review of the complications associated with treatment of oropharyngeal cancer: a guide ...
23564268 - Does robotic prostatectomy meet its promise in the management of prostate cancer?
23140298 - Medicinal properties of the jamaican pepper plant pimenta dioica and allspice.
21176918 - Tetrandrine induces apoptosis and triggers caspase cascade in human bladder cancer cells.
16718848 - Evolution in the treatment of metastatic colorectal carcinoma of the liver.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-4-25
Journal Detail:
Title:  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico     Volume:  -     ISSN:  1699-3055     ISO Abbreviation:  Clin Transl Oncol     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-4-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101247119     Medline TA:  Clin Transl Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Servicio de Oncología Médica, Instituto Valenciano de Oncología (IVO), C/Beltrán Báguena, 8, 46009, Valencia, Spain,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3...
Next Document:  Ependymoma in children: molecular considerations and therapeutic insights.